http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104745591-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12M1-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12M1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 |
| filingDate | 2013-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104745591-B |
| titleOfInvention | CYP4V2 gene mutant and application thereof |
| abstract | The invention discloses a CYP4V2 gene mutant and application thereof, in particular to a separated nucleic acid for coding the CYP4V2 mutant, a separated polypeptide, a method for screening a biological sample susceptible to primary crystalline retinal degeneration, a system for screening the biological sample susceptible to primary crystalline retinal degeneration and a kit for screening the biological sample susceptible to primary crystalline retinal degeneration. Wherein the isolated nucleic acid encoding the CYP4V2 mutant has substantial homology to SEQ ID NO: 1 compared to 1, with the c.413+2T > G mutation. By detecting whether the novel mutant exists in a biological sample, whether the biological sample is susceptible to primary crystalline retinal degeneration can be effectively detected. |
| priorityDate | 2013-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 62.